In terms of clinical advantages, Bcl-2 inhibitors have been shown to be uniquely safe and well established in the treatment of hematologic malignancies such as chronic lymphocytic leukemia (CLL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and follicular lymphoma (FL) [87]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.